OBJECTIVES: To develop a patient-based, disease-specific measure of the health impact of
multiple sclerosis (MS) for use in clinical trials and clinical practice. DATA SOURCES …

Abstract Changes in health policy have underlined the importance of evidence-based
clinical practice and rigorous evaluation of patient-based outcomes. As patient-based …

The selection of measures of quality of life used in clinical trials of multiple sclerosis (MS)
should be evidence-based. Head-to-head comparison of measures facilitates the selection …

Multiple patient‐reported outcomes (PROs) are currently being used in multiple sclerosis
(MS) but their application is inconsistent and guidance on the appropriateness of each tool …

Quantifying the clinical impact of multiple sclerosis (MS) is a critical issue for judging
experimental therapies tested in clinical trials, and, in everyday practice, for optimizing …

OBJECTIVES Understanding the properties of an outcome measure is essential in choosing
the appropriate instrument and interpreting the information it generates. The MOS 36 item …

The feasibility and precision of clinical trials for the treatment of MS must be improved
Subsequent to the approval by the Food and Drug Administration of the United States of …

This article provides recommendations from the National Multiple Sclerosis Society's Clinical
Outcomes Assessment Task Force. The Task Force was appointed in 1994 and charged …

Objectives: To compare the responsiveness of the Multiple Sclerosis Impact Scale (MSIS-29)
with other self report scales in three multiple sclerosis (MS) samples using a range of …

The primary clinical outcome measure for evaluating multiple sclerosis in clinical trials has
been Kurtzke's expanded disability status scale (EDSS). New therapies appear to favourably …